Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

Si-Yu Zhang,Xin-Yu Song,Yang Li,Lin-Lin Ye,Qiong Zhou,Wei-Bing Yang

DOI: https://doi.org/10.1016/j.phrs.2020.105111

IF: 10.334

2020-11-01

Pharmacological Research

Abstract:<p>Macrophages, a type of myeloid immune cell, play essential roles in fighting against pathogenic invasion and activating T cell-mediated adaptive immune responses. As a major constituent of the tumor microenvironment (TME), macrophages play a complex role in tumorigenesis and tumor progression. They can inhibit tumor growth by releasing proinflammatory cytokines and exerting cytotoxic activities but principally contribute to tumor progression by promoting tumor proliferation, angiogenesis, and metastasis. The tumor-promoting hallmarks of macrophages have aroused widespread interest in targeting tumor-associated macrophages (TAMs) for cancer immunotherapy. Increasing preclinical and clinical studies suggest that TAMs are a promising target for cancer immunotherapy. To date, TAM-targeted therapeutic strategies have mainly been divided into two kinds: inhibiting pro-tumor TAMs and activating anti-tumor TAMs. We reviewed the heterogeneous and plastic characteristics of macrophages in the TME and the feasible strategies to target TAMs in cancer immunotherapy and summarized the complementary effect of TAM-targeted therapy with traditional treatments or other immunotherapies.</p>

pharmacology & pharmacy

What problem does this paper attempt to address?

The paper attempts to address the complex roles of tumor-associated macrophages (TAMs) in the tumor microenvironment and their potential as targets for cancer immunotherapy. Specifically, the paper explores the following points:

1. **Heterogeneity and Plasticity of TAMs**: The paper discusses in detail the origins, polarization states, and functional diversity of TAMs. TAMs can originate from different cellular precursors, including the embryonic yolk sac, fetal liver, and bone marrow, and these different sources of TAMs play various roles in tumors. Additionally, TAMs can be classified based on their activation states into pro-inflammatory (M1) and anti-inflammatory (M2) types, but this classification is overly simplistic as TAMs exhibit a dynamic phenotypic spectrum.

2. **Relationship Between TAMs and Tumor Prognosis**: The paper points out that the impact of TAMs on prognosis varies across different types of tumors. For example, in lung and breast cancers, a high density of TAMs is generally associated with poorer prognosis, whereas in colorectal cancer, the role of TAMs is more complex and can sometimes be associated with a favorable prognosis.

3. **Immunotherapy Strategies Targeting TAMs**: The paper reviews two main current immunotherapy strategies targeting TAMs:
- **Inhibiting Pro-tumor TAMs**: This includes methods to prevent the recruitment of monocytes to the tumor and reduce the number of TAMs. For example, blocking the CCL2/CCR2 axis or the CSF-1/CSF-1R axis to reduce the recruitment and survival of TAMs.
- **Activating Anti-tumor TAMs**: This involves reprogramming pro-tumor TAMs into anti-tumor TAMs. This can be achieved through the use of anti-CD47 antibodies, CD40 agonists, PI3Kγ inhibitors, and class II histone deacetylase (HDAC) inhibitors.

In summary, the paper aims to comprehensively explore the roles of TAMs in the tumor microenvironment and propose various immunotherapy strategies targeting TAMs, with the goal of providing new insights and methods for cancer treatment.